TY - JOUR
T1 - Prediagnostic antibodies to serum p53 and subsequent colorectal cancer
AU - Teras, Lauren R.
AU - Gapstur, Susan M.
AU - Maliniak, Maret L.
AU - Jacobs, Eric J.
AU - Gansler, Ted
AU - Michel, Angelika
AU - Pawlita, Michael
AU - Waterboer, Tim
AU - Campbell, Peter T.
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: The presence of circulating antibodies to the p53 tumor suppressor protein is a potential early detection colorectal cancer biomarker. However, studies of prediagnostic measures of p53 seropositivity in relation to colorectal cancer risk are limited. Methods: We conducted a nested case–control study of serum p53 autoantibodies and risk of colorectal cancer within the Cancer Prevention Study- II Nutrition Cohort. Among cohort participants who were cancer free at the time of blood collection, 392 were subsequently diagnosed with colorectal cancer over 11 years of follow-up. Two controls were matched to each case on birth date, blood draw date, race, and sex. Autoantibodies to p53 were detected in 41 of the 392 cases (10.5%) and 49 of the 774 controls (6.3%). Results: Participants who were seropositive for p53 antibodies before diagnosis were more likely to be subsequently diagnosed with colorectal cancer [RR ¼ 1.77; 95% confidence interval (CI), 1.12–2.78]. This association was strongest within 3 years of diagnosis (RR ¼ 2.26; 95% CI, 1.06–4.83). An association was also suggested when colorectal cancer was diagnosed 4 to <6 years after p53 measurement (RR ¼ 1.84; 95% CI, 0.89–3.79), but not 6 or more years later (RR ¼ 1.15; 95% CI, 0.44–2.99). Conclusions: If these results are confirmed, serum p53 antibodies May be useful on a panel of early detection markers for colorectal cancer. Impact: Individuals who were seropositive for p53 antibodies were twice as likely to develop colorectal cancer within the next 3 years compared with those who were seronegative. This marker is a good candidate for inclusion on an early detection marker panel for colorectal cancer. Cancer Epidemiol Biomarkers Prev; 27(2); 219–23. 2017 AACR.
AB - Background: The presence of circulating antibodies to the p53 tumor suppressor protein is a potential early detection colorectal cancer biomarker. However, studies of prediagnostic measures of p53 seropositivity in relation to colorectal cancer risk are limited. Methods: We conducted a nested case–control study of serum p53 autoantibodies and risk of colorectal cancer within the Cancer Prevention Study- II Nutrition Cohort. Among cohort participants who were cancer free at the time of blood collection, 392 were subsequently diagnosed with colorectal cancer over 11 years of follow-up. Two controls were matched to each case on birth date, blood draw date, race, and sex. Autoantibodies to p53 were detected in 41 of the 392 cases (10.5%) and 49 of the 774 controls (6.3%). Results: Participants who were seropositive for p53 antibodies before diagnosis were more likely to be subsequently diagnosed with colorectal cancer [RR ¼ 1.77; 95% confidence interval (CI), 1.12–2.78]. This association was strongest within 3 years of diagnosis (RR ¼ 2.26; 95% CI, 1.06–4.83). An association was also suggested when colorectal cancer was diagnosed 4 to <6 years after p53 measurement (RR ¼ 1.84; 95% CI, 0.89–3.79), but not 6 or more years later (RR ¼ 1.15; 95% CI, 0.44–2.99). Conclusions: If these results are confirmed, serum p53 antibodies May be useful on a panel of early detection markers for colorectal cancer. Impact: Individuals who were seropositive for p53 antibodies were twice as likely to develop colorectal cancer within the next 3 years compared with those who were seronegative. This marker is a good candidate for inclusion on an early detection marker panel for colorectal cancer. Cancer Epidemiol Biomarkers Prev; 27(2); 219–23. 2017 AACR.
UR - http://www.scopus.com/inward/record.url?scp=85041384468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041384468&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-17-0407
DO - 10.1158/1055-9965.EPI-17-0407
M3 - Article
C2 - 29254936
AN - SCOPUS:85041384468
SN - 1055-9965
VL - 27
SP - 219
EP - 223
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 2
ER -